Orforglipron
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Orforglipron?
The generic name for Foundayo, and the first non-peptide GLP-1 agonist to reach approval.
Like tirzepatide, it carries an oral-contraceptive warning, because slower stomach emptying can change how well a pill is absorbed. Anyone relying on the contraceptive pill should use a non-oral option, or back it up with a barrier method, for 30 days from the first dose and from every dose step-up.
Related reading: Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Orforglipron comes up on this site
On GLP Watchdog, Orforglipron comes up in 12 research articles, 21 seller reviews and 2 tools.
Research that discusses it
- Foundayo (Orforglipron) Side Effects: Rates by Dose, Dropouts and Interactions
- Foundayo Cost: Orforglipron Price by Dose, Insurance and Medicare
- Appetite Suppressants: Every FDA-Approved Drug and What Its Label Shows
- How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
- Does Missouri Medicaid Cover Zepbound and Wegovy? MO HealthNet's GLP-1 Rules
- The Top Dose Keeps Not Being Worth It
- All 12 articles are on the research page
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers